XML 23 R11.htm IDEA: XBRL DOCUMENT
v3.8.0.1

FAIR VALUE MEASUREMENTS | 9 Months Ended
--- | ---
Sep. 27, 2017
Fair Value Disclosures [Abstract] |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS
Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables present information about our financial assets and liabilities measured at fair value on a recurring basis as of September 27, 2017 and December 28, 2016, and indicate the classification within the fair value hierarchy. Cash, Cash Equivalents and Marketable Securities The following tables summarize our cash, cash equivalents and marketable securities by significant investment categories as of September 27, 2017 and December 28, 2016:
|  | September 27, 2017 |
| Cost Basis |  |  | Gross Unrealized Gains |  |  | Gross Unrealized Losses |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Marketable Securities |
Cash | $ | 21,862 |  |  | $ | — |  |  | $ | — |  |  | $ | 21,862 |  |  | $ | 21,862 |  |  | $ | — |
Level 1: |  |  |  |  |  |  |  |  |  |  |
| Money market funds | 5,025 |  |  | — |  |  | — |  |  | 5,025 |  |  | 5,025 |  |  | — |
| Mutual funds | 60,769 |  |  | 60 |  |  | — |  |  | 60,829 |  |  | — |  |  | 60,829 |
Level 2: |  |  |  |  |  |  |  |  |  |  |
| Corporate debt securities(1) | 2,493 |  |  | 2 |  |  | (25 | ) |  | 2,470 |  |  | — |  |  | 2,470 |
Total | $ | 90,149 |  |  | $ | 62 |  |  | $ | (25 | ) |  | $ | 90,186 |  |  | $ | 26,887 |  |  | $ | 63,299 |
|  | December 28, 2016 |
| Cost Basis |  |  | Gross Unrealized Gains |  |  | Gross Unrealized Losses |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Marketable Securities |
Cash | $ | 6,322 |  |  | $ | — |  |  | $ | — |  |  | $ | 6,322 |  |  | $ | 6,322 |  |  | $ | — |
Level 1: |  |  |  |  |  |  |  |  |  |  |
| Money market funds | 5,285 |  |  | — |  |  | — |  |  | 5,285 |  |  | 5,285 |  |  | — |
| Mutual funds | 60,232 |  |  | — |  |  | — |  |  | 60,232 |  |  | — |  |  | 60,232 |
Level 2: |  |  |  |  |  |  |  |  |  |  |
| Corporate debt securities(1) | 2,473 |  |  | 3 |  |  | (30 | ) |  | 2,446 |  |  | — |  |  | 2,446 |
Total | $ | 74,312 |  |  | $ | 3 |  |  | $ | (30 | ) |  | $ | 74,285 |  |  | $ | 11,607 |  |  | $ | 62,678 |
(1) | Corporate debt securities were measured at fair value using a market approach utilizing observable prices for identical securities or securities with similar characteristics and inputs that are observable or can be corroborated by observable market data.
Net unrealized gains on available-for-sale securities totaling $37 and net unrealized losses on available-for-sale securities totaling $27 were included in accumulated other comprehensive income (loss) on the Condensed Consolidated Balance Sheet as of September 27, 2017 and December 28, 2016, respectively. The following tables summarize the gross unrealized losses and fair values for those investments that were in an unrealized loss position as of September 27, 2017 and December 28, 2016, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:
|  | September 27, 2017 |
|  | Less than 12 Months |  |  | 12 Months or Greater |  |  | Total |
| Fair Value |  |  | Unrealized Loss |  |  | Fair Value |  |  | Unrealized Loss |  |  | Fair Value |  |  | Unrealized Loss |
| Money market funds | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
| Mutual funds | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
| Corporate debt securities | 1,638 |  |  | (9 | ) |  | 322 |  |  | (16 | ) |  | 1,960 |  |  | (25 | )
Total | $ | 1,638 |  |  | $ | (9 | ) |  | $ | 322 |  |  | $ | (16 | ) |  | $ | 1,960 |  |  | $ | (25 | )
|  | December 28, 2016 |
|  | Less than 12 Months |  |  | 12 Months or Greater |  |  | Total |
| Fair Value |  |  | Unrealized Loss |  |  | Fair Value |  |  | Unrealized Loss |  |  | Fair Value |  |  | Unrealized Loss |
| Money market funds | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
| Mutual funds | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
| Corporate debt securities | 1,244 |  |  | (10 | ) |  | 540 |  |  | (20 | ) |  | 1,784 |  |  | (30 | )
Total | $ | 1,244 |  |  | $ | (10 | ) |  | $ | 540 |  |  | $ | (20 | ) |  | $ | 1,784 |  |  | $ | (30 | )
A summary of other income from available-for-sale securities recognized during the thirteen and thirty-nine weeks ended September 27, 2017 and September 28, 2016 is as follows:
|  | Thirteen Weeks Ended |  |  | Thirty-Nine Weeks Ended |
| September 27 2017 |  |  | September 28 2016 |  |  | September 27 2017 |  |  | September 28 2016 |
Available-for-sale securities: |  |  |  |  |  |  |
| Dividend income | $ | 222 |  |  | $ | 133 |  |  | $ | 591 |  |  | $ | 133 |
| Interest income | 19 |  |  | 22 |  |  | 58 |  |  | 68 |
| Loss on investments | (12 | ) |  | (4 | ) |  | (27 | ) |  | (4 | )
Total other income, net | $ | 229 |  |  | $ | 151 |  |  | $ | 622 |  |  | $ | 197 |
A summary of available-for-sale securities sold and gross realized gains and losses recognized during the thirteen and thirty-nine weeks ended September 27, 2017 and September 28, 2016 is as follows:
|  | Thirteen Weeks Ended |  |  | Thirty-Nine Weeks Ended |
| September 27 2017 |  |  | September 28 2016 |  |  | September 27 2017 |  |  | September 28 2016 |
Available-for-sale securities: |  |  |  |  |  |  |
| Gross proceeds from sales and redemptions | $ | 584 |  |  | $ | 176 |  |  | $ | 1,212 |  |  | $ | 498 |
| Cost basis of sales and redemptions | 597 |  |  | 180 |  |  | 1,239 |  |  | 502 |
| Gross realized gains included in net income | 1 |  |  | — |  |  | 1 |  |  | 1 |
| Gross realized losses included in net income | (13 | ) |  | (4 | ) |  | (28 | ) |  | (5 | )
| Amounts reclassified out of accumulated other comprehensive loss | 14 |  |  | 3 |  |  | 28 |  |  | 3 |
Realized gains and losses are determined on a specific identification method and are included in other income, net on the Condensed Consolidated Statements of Income. The estimated fair value of our investments in corporate debt securities that are accounted for as available-for-sale securities are all due within one year and are included within marketable securities on the Condensed Consolidated Balance Sheets. We periodically review our marketable securities for other-than-temporary impairment. We consider factors such as the duration, severity and the reason for the decline in value, the potential recovery period and our intent to sell. For our debt securities, we also consider whether (i) it is more likely than not that we will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. As of September 27, 2017 and December 28, 2016, the declines in the market value of our marketable securities investment portfolio were considered to be temporary in nature. Other Financial Instruments The carrying value of our other financial instruments, including accounts receivable, accounts payable, and accrued expenses as of September 27, 2017 and December 28, 2016 approximated their fair value due to the short-term nature of these financial instruments. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Assets and liabilities that are measured at fair value on a non-recurring basis include our long-lived assets and indefinite-lived intangible assets. There were no impairments recognized during the thirteen and thirty-nine weeks ended September 27, 2017 and September 28, 2016.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -URI http://asc.fasb.org/topic&trid=2155941 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration